Addressing unmet needs in rare diseases and systemic complement mediated disorders

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenience

Superior Outcomes

A leader in the field of engineered protease biopharmaceuticals

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenience

Superior Outcomes

Protease engineering platform – hemophilia assets in development and a SQ systemic complement research program

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenience

Superior Outcomes

Next Generation Protease Drugs

Learn more about our Pipeline

SQ Marzeptacog alfa (activated) “MarzAA”
Hemophilia A or B w Inhibitors – ToB
Phase 3 Ready
SQ Marzeptacog alfa (activated) “MarzAA”
FVIID/Glanzmann/Hemlibra – ToB
Phase 1/2
SQ Dalcinonacog alfa “DalcA”
Hemophilia B (rFIX)
Phase 2
FIX-Gene Therapy
Hemophilia B (CB 2679d-GT)
Preclinical
IVT CB 2782-PEG
anti-C3 protease for Dry AMD
Preclinical
SQ Systemic complement inhibitors
 
Research

Essential Medicines – Superior Outcomes

Late-Stage Asset

SQ Marzeptacog alfa (activated)
MarzAA (FVIIa)

Phase 3 Ready

 

Hemophilia

SQ MarzAA (FVIIa)

SQ Dalcinonacog alfa – DalcA (FIX)

Factor IX Gene Therapy

Factor Xa

Complement

IVT Anti-C3 Dry AMD CB 2782-PEG

SQ Systemic Complement Inhibitors

 

Protease Engineering Platform

The Catalyst Advantage

Drug candidates for severe medical conditions

Learn more about the medicines we are developing

See our pipeline

Addressing diseases with unmet medical needs

Share our passion about treating disease

Learn more about our pipeline

Experienced and passionate team

Learn more about the Catalyst team and mission/culture

Meet the team